Understanding HTLV-I EnzymologyandPreparation and Characterization of Lead Inhibitors for the Treatment of HTLV-I Infection

Enzymology;Fluorescence quenching;HTLV-I (Virus);Kinetics;Mutation (Biology);Protease inhibitors

Dennison, Kelly Joy ; Chemistry and Biochemistry

University:Georgia Institute of Technology

Department:Chemistry and Biochemistry

关键词: Enzymology;    Fluorescence quenching;    HTLV-I (Virus);    Kinetics;    Mutation (Biology);    Protease inhibitors;   

Others  :  https://smartech.gatech.edu/bitstream/1853/7582/1/dennison_kelly_j_200512_phd.pdf

美国|英语

来源: SMARTech Repository

【 摘 要 】

The primary goals of our research are to understand the virology and enzymology of human T-cell leukemia virus type I (HTLV-I) that will lead to the development of treatments for patients infected with HTLV-I. HTLV-I is an oncogenic virus of the Retroviridae family and is the causative agent of adult T-cell leukemia/lymphoma (ATL), tropical spastic paraparesis/HTLV-I associated myelopathy (TSP/HAM). HTLV-I has been classified as a dangerous emerging pathogen by the Centers for Disease ControlandPrevention with at least 20 million people infected with the virus. This is a significant problem because there are currently no effective treatments to control HTLV-I infection and prevent or treat HTLV-I induced ATL and TSP/HAM.The protease is necessary for retroviral maturation and replication and is, therefore, an attractive target for inhibitor design.Investigation of peptide mimetic compounds incorporating the tetrahedral intermediate of aspartyl protease catalyzed cleavage are crucial for the development of lead inhibitors. Compounds containing statine, 4-amino-3-hydroxy-5-phenylpentanoic acid (AHPPA), or hydroxyethylamine (HEA) are presented in this work. The best compound was a statine-based inhibitor, which had a Ki = 29 +/- 4 nM and 88% inhibition against an HTLV-I protease native substrate in a FRET assay.